EFFECTS OF PROGESTERONE RECEPTOR ON PROLIFERATION OF UTERINE LEIOMYOMA CELLS

S. Liao, HN. Mi, LY. Chai, HN. Wang

Article ID: 5062
Vol 33, Issue 6, 2019
DOI: https://doi.org/10.23812/19-170-A
Received: 4 June 2019; Accepted: 4 June 2019; Available online: 8 January 2020; Issue release: 8 January 2020

Abstract

In order to study the mechanism of the effect of progesterone receptor on the growth of primary uterine leiomyoma cells, the primary cells were extracted from uterine leiomyoma cells and identified by immunohistochemistry (IHC). Mitochondrial progesterone receptor-positive [PR-M(+)], mitochondrial progesterone receptor-negative [PR-M(-)], progesterone receptor A (PR-A) and progesterone receptor B (PR-B) were screened by Western blotting. Different concentrations of Mifepristone (MIF), a progesterone receptor antagonist, were used to interfere with PR-M(+) and PR-M(-) cell lines, respectively. Proliferation and apoptosis of PR-M(+) and PR-M(-) cell lines were detected by tetramethylazolyl blue method and flow cytometry, respectively. The expression of Caspase-3 and B-cell lymphoma 2 (Bcl-2) protein was detected by Western blotting. The results showed that the growth of PR-M(+) and PR-M(-) uterine leiomyoma cells was inhibited with the increase of MIF concentration. Furthermore, the proliferation inhibition rate and apoptosis rate were gradually increased. However, the expression of Caspase-3 protein on progesterone receptor M increased, while the expression of Bcl-2 decreased. Moreover, progesterone could induce progesterone receptor M to up-regulate apoptotic protein Caspase-3 and down-regulate anti-apoptotic protein Bcl-2, thus it could inhibit the apoptosis of primary cultured uterine leiomyoma cells and promote the proliferation of leiomyoma cells.


Keywords

progesterone receptor;uterine leiomyoma;cell proliferation;primary culture


References

Supporting Agencies



Copyright (c) 2019 S. Liao, HN. Mi, LY. Chai, HN. Wang




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).